Drug intelligence / Profile preview

oxytetracycline + flunixin

Development stage
Unknown
Lead developer
Delta Pharma
Modality
Small Molecules
Administration
Intramuscular
01

Overview

Delta Oxy Plus L.A. is a long-acting injectable veterinary formulation developed by Wayzon Pharma, combining the broad-spectrum antibiotic oxytetracycline with the non-steroidal anti-inflammatory drug (NSAID) flunixin. Oxytetracycline exerts its antimicrobial effect by binding to the 30S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis. Flunixin meglumine provides potent anti-inflammatory, analgesic, and antipyretic activity by inhibiting cyclooxygenase (COX) enzymes, which are responsible for prostaglandin synthesis. This combination is specifically designed for the treatment of systemic and local infections in livestock, such as bovine respiratory disease (BRD), where the management of associated pain and fever is clinically beneficial alongside antibiotic therapy.

Brand names
Delta Oxy Plus L.A.
Other names
Delta Oxy Plus LA
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)30S A-site (Bacterial ribosomal 30S A-site)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on oxytetracycline + flunixin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxytetracycline + flunixin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call